ABSTRACT
Background Administrative data permits analysis of large cohorts but relies on International Classification of Diseases, Ninth and Tenth Revision, Clinical Modification (ICD) codes that may not reflect true congenital heart defects (CHD).
Methods 1497 cases with at least one encounter between 1/1/2010 – 12/31/2019 in two healthcare systems (one adult, one pediatric) identified by at least one of 87 ICD CHD codes were validated through chart review for the presence of CHD and CHD anatomic group.
Results Inter- and intra-observer reliability averaged > 95%. Positive predictive value (PPV) of ICD codes for CHD was 68.1% (1020/1497) overall, 94.6% (123/130) for cases identified in both healthcare systems, 95.8% (249/260) for severe codes, 52.6% (370/703) for shunt codes, 75.9% (243/320) for valve codes, 73.5% (119/162) for shunt and valve codes, and 75.0% (39/52) for “Other CHD” (7 ICD codes). PPV for cases with >1 unique CHD code was 85.4% (503/589) vs. 56.3% (498/884) for one CHD code. Of cases with secundum atrial septal defect ICD codes 745.5/Q21.1 in isolation, 30.9% (123/398) had a confirmed CHD. Patent foramen ovale was present in 66.2% (316/477) of false positives (FP). The median number of unique CHD-coded encounters was higher for true positives (TP) than FP (2.0; interquartile range [IQR]: 1.0-3.0 vs 1.0; IQR:1.0-1.0, respectively, p<0.0001). TP had younger mean age at first encounter with a CHD code than FP (22.4 years vs 26.3 years, p=0.0017).
Conclusion PPV of CHD ICD codes varies by characteristics for detection of CHD by ICD code and anatomic grouping. While an ICD code for severe CHD and/or the presence of a case in more than one data source, regardless of anatomic group, is associated with higher PPV for CHD, most TP cases did not have these characteristics. The development of algorithms to improve accuracy may improve administrative data for CHD surveillance.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The work was funded by Centers for Disease Control and Prevention cooperative agreement, DD19-1902
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Emory University IRB approved study. Details are included in methods
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Author email addresses: Lindsey C. Ivey, lindsey.carrie.ivey{at}emory.edu; Fred H. Rodriguez III, fred.rodriguez{at}emory.edu; Haoming Shi, haoming.shi{at}emory.edu; Cohen Chong, cohenchong3712{at}outlook.com; Joy Chen, joywchen{at}berkeley.edu; Cheryl Raskind-Hood, craskin{at}emory.edu; Karrie F. Downing, yyx9{at}cdc.gov; Sherry L. Farr, bwa0{at}cdc.gov
Disclaimer: The findings and conclusion in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention(CDC). The analysis was replicated at CDC by co-author Karrie Downing.
Author CRediT statement Lindsey C. Ivey: conceptualization, methodology, investigation, resources, data curation, writing original draft and review and editing, analysis, supervision, project administration
Fred H. Rodriguez III: conceptualization, methodology, investigation, data curation, review and editing, supervision, project administration
Haoming Shi: data curation, analysis, writing review and editing
Cohen Chong: data curation
Joy Chen: data curation
Cheryl Raskind-Hood: conceptualization, methodology, analysis, writing review and editing
Karrie Downing: conceptualization, methodology, review and editing, project administration
Sherry Farr: conceptualization, methodology, review and editing, project administration
Wendy M. Book: conceptualization, methodology, investigation, data curation, writing original draft and review and editing, preparation, supervision, project administration, funding acquisition
Data Availability
The data set contains PHI and cannot be shared publicly. The analysis has been replicated.
